HealthCare Global Enterprises (HCG) Stock Overview
Provides medical and healthcare services in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HCG Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HealthCare Global Enterprises Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹600.40 |
| 52 Week High | ₹804.65 |
| 52 Week Low | ₹513.30 |
| Beta | -0.088 |
| 1 Month Change | -5.78% |
| 3 Month Change | 14.32% |
| 1 Year Change | 9.04% |
| 3 Year Change | 89.34% |
| 5 Year Change | 165.66% |
| Change since IPO | 251.11% |
Recent News & Updates
Narrative Update • Jun 22
HCG: New Cancer Hospital Expansion Will Support A Stronger Outlook
Analysts have lifted their price target on HealthCare Global Enterprises from ₹685 to ₹724, citing refreshed assumptions for revenue growth, profit margins and future P/E multiples, alongside a slightly adjusted discount rate. What's in the News HealthCare Global Enterprises plans a Special and Extraordinary Shareholders Meeting on July 8, 2026, via postal ballot in India, to seek shareholder approvals on key matters.
Narrative Update • Jun 07
HCG: Equity Raise And AOI Bid Will Drive Future Upside
Analysts now place HealthCare Global Enterprises' price target at about ₹896, down roughly ₹11 from the prior estimate of about ₹907, citing updated assumptions for revenue growth, profit margins, and future P/E multiples. What's in the News HealthCare Global Enterprises has completed a follow on equity offering of equity shares, raising ₹4.246818b through the issue of 8,294,566 common shares at ₹512 per share under a Regulation S rights offering structure.Narrative Update • May 24
HCG: Oncology Expansion Via AOI Bid Will Support Future Upside
Analysts have nudged their fair value estimate for HealthCare Global Enterprises slightly higher from ₹900 to about ₹907, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Siemens Healthineers AG is reported to be planning an exit from its India based American Oncology Institute in a potential transaction valued at around ₹15,000m to ₹20,000m, with HealthCare Global Enterprises among the bidders being considered, alongside private equity funds, as part of a wider portfolio review at Siemens Healthineers (Key Developments).Recent updates
Narrative Update • Jun 22
HCG: New Cancer Hospital Expansion Will Support A Stronger Outlook
Analysts have lifted their price target on HealthCare Global Enterprises from ₹685 to ₹724, citing refreshed assumptions for revenue growth, profit margins and future P/E multiples, alongside a slightly adjusted discount rate. What's in the News HealthCare Global Enterprises plans a Special and Extraordinary Shareholders Meeting on July 8, 2026, via postal ballot in India, to seek shareholder approvals on key matters.Narrative Update • Jun 07
HCG: Equity Raise And AOI Bid Will Drive Future Upside
Analysts now place HealthCare Global Enterprises' price target at about ₹896, down roughly ₹11 from the prior estimate of about ₹907, citing updated assumptions for revenue growth, profit margins, and future P/E multiples. What's in the News HealthCare Global Enterprises has completed a follow on equity offering of equity shares, raising ₹4.246818b through the issue of 8,294,566 common shares at ₹512 per share under a Regulation S rights offering structure.Narrative Update • May 24
HCG: Oncology Expansion Via AOI Bid Will Support Future Upside
Analysts have nudged their fair value estimate for HealthCare Global Enterprises slightly higher from ₹900 to about ₹907, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Siemens Healthineers AG is reported to be planning an exit from its India based American Oncology Institute in a potential transaction valued at around ₹15,000m to ₹20,000m, with HealthCare Global Enterprises among the bidders being considered, alongside private equity funds, as part of a wider portfolio review at Siemens Healthineers (Key Developments).Narrative Update • Apr 29
HCG: Rights Issue And Vizag Stake Increase Will Support Future Upside
Analysts have kept their price target for HealthCare Global Enterprises steady at ₹900, indicating only slight updates to revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Board meeting on Mar 30, 2026 to review an investment of up to ₹980m in HCG NCHRI LLP, a wholly owned subsidiary, and a proposed investment of up to ₹1,556.6m to acquire an additional 34% stake in Vizag Hospital from existing shareholders (company filing).Narrative Update • Apr 15
HCG: Rights Issue And Hospital Stake Increases Will Drive Future Upside
Analysts have kept the price target for HealthCare Global Enterprises steady at ₹900. This reflects only fine tuning to revenue growth, profit margin and future P/E assumptions rather than a broad change in outlook.Narrative Update • Apr 01
HCG: Rights Issue And Hospital Investments Will Support Future Upside
Analysts have kept the price target for HealthCare Global Enterprises steady at ₹900, citing slightly higher revenue growth and profit margin assumptions along with a somewhat lower future P/E multiple in their updated model. What's in the News Board meeting scheduled on Mar 30, 2026, to consider investment of up to ₹980 million in HCG NCHRI LLP, a wholly owned subsidiary, and up to ₹1,556.6 million for acquiring an additional 34% stake in Vizag Hospital from existing shareholders (company filing).Narrative Update • Mar 18
HCG: Rights Issue And Margin Outlook Will Support Future Upside
Analysts have kept the fair value estimate for HealthCare Global Enterprises steady at ₹900, citing updated assumptions for revenue growth at 16.88%, profit margin at 11.90% and a slightly lower future P/E of 36.99x compared with prior inputs. What's in the News HealthCare Global Enterprises has filed a follow on equity offering of ₹4.25b through a rights issue of common equity shares under Regulation S.
Narrative Update • Mar 04
HCG: Rights Issue Plans Will Support Fair Outlook And Governance Gains
Analysts have revised their price target on HealthCare Global Enterprises from ₹787.71 to ₹761.14, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News HealthCare Global Enterprises has filed a follow-on equity offering of ₹4.25b in equity shares, structured as a Regulation S rights offering to existing shareholders (Key Developments).Narrative Update • Feb 17
HCG: Rights Issue Plan And Margin Outlook Will Support Future Upside
Analysts have lifted their price target on HealthCare Global Enterprises from ₹857.76 to ₹900.00. They cite updated assumptions that reflect a slightly different revenue growth outlook, higher profit margin expectations, a revised discount rate, and a lower future P/E multiple.Narrative Update • Feb 03
HCG: Governance Reset And Kenya Expansion Will Support A Stronger Outlook
Analysts have maintained their fair value estimate for HealthCare Global Enterprises at ₹685.00. They have made slight adjustments to assumptions on revenue growth, profit margins and future P/E, which refine rather than overhaul their price expectations.Narrative Update • Jan 20
HCG: Governance Changes And Kenya Expansion Will Shape A Balanced Forward Outlook
Analysts have maintained the fair value estimate for HealthCare Global Enterprises at ₹685.0. The latest narrative reflects updated assumptions that include slightly higher revenue growth, a modestly stronger profit margin, and a lower future P/E multiple. What's in the News Board meeting on November 12, 2025, to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, and to consider an investment of up to 10% in Cancer Care Kenya Limited along with a Standby Letter of Credit guarantee for its business expansion (company filing).Narrative Update • Jan 06
HCG: Future P/E Repricing Will Support Fair Outlook And Governance Gains
Analysts have nudged their fair value estimate for HealthCare Global Enterprises higher from ₹773.71 to ₹787.71, reflecting updated assumptions around revenue growth, profit margin and future P/E expectations. What's in the News Board meeting on November 12, 2025 to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, and to consider an investment of up to 10% of the shares of Cancer Care Kenya Limited along with a Standby Letter of Credit guarantee for its expansion credit facilities (Key Developments).Narrative Update • Dec 19
HCG: Upcoming Governance Moves And Kenya Expansion Will Shape Balanced Outlook
Analysts have raised their average price target on HealthCare Global Enterprises to ₹685 from ₹590, citing a higher justified valuation multiple that more than offsets slightly softer long term growth and margin assumptions. What's in the News Board meeting scheduled on November 12, 2025, to review unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025, signaling upcoming visibility on the company’s earnings trajectory (Key Developments).Narrative Update • Dec 05
HCG: Fair Outlook Will Reflect Margin Gains And Governance Developments
Analysts have raised their price target on HealthCare Global Enterprises by approximately ₹81 to reflect slightly faster expected revenue growth, improved profit margins, and a modestly lower future price to earnings multiple in their updated valuation model. What's in the News The board has scheduled a meeting for December 01, 2025, to formally appoint Chief Internal Auditor Vijay S Shanbhag as Internal Auditor for a 6 month term under Section 138 of the Companies Act, 2013 (board filing).
New Narrative • Jan 24
Investments In AI And Genomics Will Improve Patient Outcomes
Digital initiatives and strategic acquisitions are key to revenue growth, focusing on increasing digital channel revenue and expanding patient capacity.Analysis Article • Dec 22
Pinning Down HealthCare Global Enterprises Limited's (NSE:HCG) P/S Is Difficult Right Now
There wouldn't be many who think HealthCare Global Enterprises Limited's ( NSE:HCG ) price-to-sales (or "P/S") ratio of...Analysis Article • Nov 13
HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week saw the newest second-quarter earnings release from HealthCare Global Enterprises Limited ( NSE:HCG ), an...Analysis Article • Sep 19
We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned
Key Insights HealthCare Global Enterprises' Annual General Meeting to take place on 25th of September Total pay for CEO...Analysis Article • Feb 11
HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next
HealthCare Global Enterprises Limited ( NSE:HCG ) missed earnings with its latest third-quarter results, disappointing...Analysis Article • Sep 14
We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation
Key Insights HealthCare Global Enterprises' Annual General Meeting to take place on 20th of September CEO Raj Gore's...Analysis Article • Sep 05
A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)
Key Insights Using the 2 Stage Free Cash Flow to Equity, HealthCare Global Enterprises fair value estimate is ₹377...Analysis Article • May 17
HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that HealthCare Global Enterprises Limited's ( NSE:HCG ) price-to-sales (or "P/S") ratio of...Shareholder Returns
| HCG | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -2.4% | 0.9% | -0.5% |
| 1Y | 9.0% | 9.0% | -2.3% |
Return vs Industry: HCG matched the Indian Healthcare industry which returned 9% over the past year.
Return vs Market: HCG exceeded the Indian Market which returned -2.3% over the past year.
Price Volatility
| HCG volatility | |
|---|---|
| HCG Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: HCG has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HCG's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,736 | Manish Mattoo | www.hcgoncology.com |
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services.
HealthCare Global Enterprises Limited Fundamentals Summary
| HCG fundamental statistics | |
|---|---|
| Market cap | ₹89.64b |
| Earnings (TTM) | ₹137.60m |
| Revenue (TTM) | ₹25.45b |
651.5x
P/E Ratio3.5x
P/S RatioIs HCG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCG income statement (TTM) | |
|---|---|
| Revenue | ₹25.45b |
| Cost of Revenue | ₹16.20b |
| Gross Profit | ₹9.25b |
| Other Expenses | ₹9.12b |
| Earnings | ₹137.60m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 36.36% |
| Net Profit Margin | 0.54% |
| Debt/Equity Ratio | 64.6% |
How did HCG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 00:15 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HealthCare Global Enterprises Limited is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Gaurav Tinani | Ambit Capital |